IBDEI08R ; ; 12-JAN-2012
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JAN 12, 2012
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11725,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,11725,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,11725,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,11726,0)
 ;;=281.1^^88^701^110
 ;;^UTILITY(U,$J,358.3,11726,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11726,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,11726,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,11726,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,11727,0)
 ;;=286.7^^88^701^44
 ;;^UTILITY(U,$J,358.3,11727,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11727,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,11727,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,11727,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,11728,0)
 ;;=289.9^^88^701^106
 ;;^UTILITY(U,$J,358.3,11728,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11728,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,11728,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,11728,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,11729,0)
 ;;=451.9^^88^701^107
 ;;^UTILITY(U,$J,358.3,11729,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11729,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,11729,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,11729,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,11730,0)
 ;;=446.6^^88^701^108
 ;;^UTILITY(U,$J,358.3,11730,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11730,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,11730,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,11730,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,11731,0)
 ;;=286.4^^88^701^111
 ;;^UTILITY(U,$J,358.3,11731,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11731,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,11731,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,11731,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,11732,0)
 ;;=204.00^^88^701^4
 ;;^UTILITY(U,$J,358.3,11732,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11732,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,11732,1,5,0)
 ;;=5^All, W/O Remission
 ;;^UTILITY(U,$J,358.3,11732,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,11733,0)
 ;;=204.01^^88^701^3
 ;;^UTILITY(U,$J,358.3,11733,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11733,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,11733,1,5,0)
 ;;=5^All, In Remission
 ;;^UTILITY(U,$J,358.3,11733,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,11734,0)
 ;;=204.10^^88^701^41
 ;;^UTILITY(U,$J,358.3,11734,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11734,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,11734,1,5,0)
 ;;=5^Cll, W/O Remission
 ;;^UTILITY(U,$J,358.3,11734,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,11735,0)
 ;;=204.11^^88^701^40
 ;;^UTILITY(U,$J,358.3,11735,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11735,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,11735,1,5,0)
 ;;=5^Cll, In Remission
 ;;^UTILITY(U,$J,358.3,11735,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,11736,0)
 ;;=201.90^^88^701^71
 ;;^UTILITY(U,$J,358.3,11736,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11736,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,11736,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,11736,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,11737,0)
 ;;=785.6^^88^701^77
 ;;^UTILITY(U,$J,358.3,11737,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11737,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,11737,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,11737,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,11738,0)
 ;;=200.20^^88^701^78
 ;;^UTILITY(U,$J,358.3,11738,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11738,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,11738,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,11738,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,11739,0)
 ;;=202.00^^88^701^80
 ;;^UTILITY(U,$J,358.3,11739,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11739,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,11739,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,11739,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,11740,0)
 ;;=200.10^^88^701^79
 ;;^UTILITY(U,$J,358.3,11740,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11740,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,11740,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,11740,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,11741,0)
 ;;=273.3^^88^701^81
 ;;^UTILITY(U,$J,358.3,11741,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11741,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,11741,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,11741,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,11742,0)
 ;;=203.00^^88^701^90
 ;;^UTILITY(U,$J,358.3,11742,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11742,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,11742,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,11742,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,11743,0)
 ;;=203.01^^88^701^89
 ;;^UTILITY(U,$J,358.3,11743,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11743,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,11743,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,11743,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,11744,0)
 ;;=238.6^^88^701^93
 ;;^UTILITY(U,$J,358.3,11744,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11744,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,11744,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,11744,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,11745,0)
 ;;=205.00^^88^701^6
 ;;^UTILITY(U,$J,358.3,11745,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11745,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,11745,1,5,0)
 ;;=5^Aml, W/O Remission
 ;;^UTILITY(U,$J,358.3,11745,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,11746,0)
 ;;=205.01^^88^701^5
 ;;^UTILITY(U,$J,358.3,11746,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11746,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,11746,1,5,0)
 ;;=5^Aml, In Remission
 ;;^UTILITY(U,$J,358.3,11746,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,11747,0)
 ;;=205.10^^88^701^43
 ;;^UTILITY(U,$J,358.3,11747,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11747,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,11747,1,5,0)
 ;;=5^Cml, W/O Remission
 ;;^UTILITY(U,$J,358.3,11747,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,11748,0)
 ;;=205.11^^88^701^42
 ;;^UTILITY(U,$J,358.3,11748,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11748,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,11748,1,5,0)
 ;;=5^Cml, In Remission
 ;;^UTILITY(U,$J,358.3,11748,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,11749,0)
 ;;=289.0^^88^701^45
 ;;^UTILITY(U,$J,358.3,11749,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11749,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,11749,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,11749,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,11750,0)
 ;;=238.4^^88^701^94
 ;;^UTILITY(U,$J,358.3,11750,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11750,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,11750,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,11750,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,11751,0)
 ;;=V58.61^^88^701^112
 ;;^UTILITY(U,$J,358.3,11751,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11751,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,11751,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,11751,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,11752,0)
 ;;=282.49^^88^701^104
 ;;^UTILITY(U,$J,358.3,11752,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11752,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,11752,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,11752,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,11753,0)
 ;;=289.89^^88^701^13
 ;;^UTILITY(U,$J,358.3,11753,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11753,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,11753,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,11753,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,11754,0)
 ;;=238.79^^88^701^76
 ;;^UTILITY(U,$J,358.3,11754,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11754,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,11754,1,5,0)
 ;;=5^LYMPH/HEMATPOITC TIS NEC
 ;;^UTILITY(U,$J,358.3,11754,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,11755,0)
 ;;=287.30^^88^701^95
 ;;^UTILITY(U,$J,358.3,11755,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11755,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,11755,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,11755,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,11756,0)
 ;;=288.09^^88^701^2
 ;;^UTILITY(U,$J,358.3,11756,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11756,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,11756,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,11756,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,11757,0)
 ;;=V10.21^^88^701^51
 ;;^UTILITY(U,$J,358.3,11757,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11757,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,11757,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,11757,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,11758,0)
 ;;=284.2^^88^701^91
 ;;^UTILITY(U,$J,358.3,11758,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11758,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,11758,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,11758,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,11759,0)
 ;;=202.40^^88^701^64
 ;;^UTILITY(U,$J,358.3,11759,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11759,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,11759,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,11759,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,11760,0)
 ;;=287.49^^88^701^105
 ;;^UTILITY(U,$J,358.3,11760,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11760,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,11760,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,11760,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,11761,0)
 ;;=465.9^^88^702^67
 ;;^UTILITY(U,$J,358.3,11761,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11761,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,11761,1,5,0)
 ;;=5^URI
 ;;^UTILITY(U,$J,358.3,11761,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,11762,0)
 ;;=462.^^88^702^58
 ;;^UTILITY(U,$J,358.3,11762,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11762,1,4,0)
 ;;=4^462.
